AI Article Synopsis
- Small-cell carcinoma of the prostate has a poor prognosis, making treatment options uncertain for advanced cases.
- A 68-year-old man with prostate cancer experienced disease progression despite initial treatments; however, a biopsy confirmed small-cell carcinoma after he developed enlarged lymph nodes.
- Treatment with a combination of chemotherapy and a PARP-2 inhibitor, olaparib, led to partial remission for 8 months, suggesting that PARP-2 inhibition could enhance survival in these patients.
Article Abstract
Introduction: Small-cell carcinoma of the prostate has a poor prognosis, and treatment options for the refractory disease are unclear.
Case Presentation: A 68-year-old man with prostate cancer was referred to our hospital. He was treated with combined androgen blockade (bicalutamide and degarelix acetate). The disease progressed to castration-resistant prostate cancer, but with additional treatment, prostate-specific antigen levels remained below 0.02 ng/mL. However, computed tomography revealed enlarged right inguinal lymph nodes; moreover, his neuron-specific enolase levels were elevated. Histopathologic analysis of a biopsied lymph node confirmed small-cell carcinoma. After administering cytotoxic chemotherapy (etoposide plus cisplatin and amrubicin), the patient temporarily improved before relapsing. After genetic testing of the biopsy specimen revealed a deletion, we administered the oral PARP-2 inhibitor olaparib, which has achieved partial remission for 8 months.
Conclusion: PARP-2 inhibition may improve the survival of patients with -positive small-cell carcinoma of the prostate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626344 | PMC |
| http://dx.doi.org/10.1002/iju5.12523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!